It is unclear whether the role of HER2 as a biomarker of poor prognosis in GC might be to the result of this difference in frequency, whereby the prognostic value might be determined by the extent of HER2 heterogeneity in HER2 positive GC. Here, ERBB2 is linked to gastric cancer.